Discover and read the best of Twitter Threads about #GBM
Most recents (14)
@annenbcnews
Hi Anne, my husband was dx w/ a #GBM in May 2022. I'm confused by how you did a GBM story w/o discussing the most significant development ever for brain tumors.
Please follow up with #UCLA & #NWBO #DCVAX. Completed P3 last May, approved for UK Specials already &
1/
Hi Anne, my husband was dx w/ a #GBM in May 2022. I'm confused by how you did a GBM story w/o discussing the most significant development ever for brain tumors.
Please follow up with #UCLA & #NWBO #DCVAX. Completed P3 last May, approved for UK Specials already &
1/
is a personalized, nontoxic vaccine. It has given patients w/ a 10-18 month prognosis 9, 12, 16, 20+ years & counting with no addtl treatment.
My husband is a 52 yo firefighter and we are counting on #DCVAX to save his life. He doesn't have time for the treatment you covered
2/
My husband is a 52 yo firefighter and we are counting on #DCVAX to save his life. He doesn't have time for the treatment you covered
2/
This vaccine was created in the US and UK will have full approval before the US, forcing US patients like @Clairotonin, a 36 yo ICU nurse who desperately needs it, to try to get to the UK at a cost of $300k
We need #DCVAX approved by @US_FDA for compassionate use ASAP and
3/
We need #DCVAX approved by @US_FDA for compassionate use ASAP and
3/
@BerkeleyJr
While I'm glad you covered #GBM tumors, you missed the headline. Instead of sharing the incredible successes of #NWBO #DCVAX and how many patients have gone 9, 12, 16, 21 years and counting w/ no addtl treatment, you focused on a Phase 2.
1/
While I'm glad you covered #GBM tumors, you missed the headline. Instead of sharing the incredible successes of #NWBO #DCVAX and how many patients have gone 9, 12, 16, 21 years and counting w/ no addtl treatment, you focused on a Phase 2.
1/
Phase 3 was presented last May. JAMA included in their journal and 60 top docs signed on. Plus the combo trial with Keytruda and Poly-ICLC is incredible.
#DCVAX is helping people NOW. It was created at UCLA and trials were conducted in the UK, CANADA, and GERMANY too.
2/
#DCVAX is helping people NOW. It was created at UCLA and trials were conducted in the UK, CANADA, and GERMANY too.
2/
Patients with #glioma often experience altered cognition but it was unknown whether tumors remodel or destroy neuronal circuits in the human brain. New, open access #CancerNeuroscience paper: nature.com/articles/s4158….
In our study led by talented @NeurosurgUCSF post doc @SarithaKrishnaa and collaborators @michelle_monje, @DavidJBrang @LabRaleigh @AnnetteMolinar2, we found that glioblastomas remodel circuits.
Intraoperative recordings in awake people with left hemisphere #GBM show us that speech production activates glioma-infiltrated cortex, and GBM remodels speech circuitry so that producing speech activates all of the glioma-infiltrated cortex.
🚀 #DeTasker's IDO is on it's way! We're committed to a fair launch, with no presale or VC backing. Don't miss out on this opportunity to be part of the future of decentralized freelancing! Learn why we chose #WigoSwap and how we're utilizing their #WigoRun and #GBM features. 
🎯 Fair Launch: #DeTasker believes in equal opportunities for all. Our decision to avoid presales and VC backing ensures a level playing field for our community members. Participate in our IDO for a truly fair and transparent token distribution.
Granted: Commercial manufacturing license (MIA) at Sawston, for CDMO Advent at the $NWBO owned factory for manufacturing #DCVaxL, it’s successful #cancervaccine for #GBM & any solid tumor ultimately.
Next step, Marketing Approval, BLA.
cms.mhra.gov.uk/mhra/mia/uk-mi…
Next step, Marketing Approval, BLA.
cms.mhra.gov.uk/mhra/mia/uk-mi…
Background:
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
From July 6, 2022
nwbio.com/northwest-biot…
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
From July 6, 2022
nwbio.com/northwest-biot…
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients w/Newly Diagnosed & Recurrent Glioblastoma: Phase 3 Prospective Externally Controlled Cohort Trial | JAMA Oncology $NWBO #DCVaxL #Phase3
jamanetwork.com/journals/jamao…
jamanetwork.com/journals/jamao…
Commercial manufacturing license for designated contract manufacturing manager for Sawston, the $NWBO factory for manufacturing #DCVaxL, it’s successful #cancervaccine for solid tumors, first for #GBM
Next step, commercial marketing approval, BLA, etc.
cms.mhra.gov.uk/mhra/mia/uk-mi
Next step, commercial marketing approval, BLA, etc.
cms.mhra.gov.uk/mhra/mia/uk-mi
Background:
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
From July 6, 2022
nwbio.com/northwest-biot…
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
From July 6, 2022
nwbio.com/northwest-biot…
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients w/Newly Diagnosed & Recurrent Glioblastoma: Phase 3 Prospective Externally Controlled Cohort Trial | JAMA Oncology $NWBO #DCVaxL #Phase3
jamanetwork.com/journals/jamao…
jamanetwork.com/journals/jamao…
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy from 2011, #DCVaxL with #PolyICLC #Glioblastoma #GBM
aacrjournals.org/clincancerres/…
aacrjournals.org/clincancerres/…
#DCVaxL & #PolyICLC #TLR3Inhibitor as adjuvant, have been an impressive combination since 2011:
Results: DC vaccinations are safe and not associated with any dose-limiting toxicity.
Results: DC vaccinations are safe and not associated with any dose-limiting toxicity.
The median overall survival from the time of initial surgical diagnosis of glioblastoma was 31.4 months, with a 1-, 2-, and 3-year survival rate of 91%, 55%, and 47%, respectively.
Relatively New Program at FDA:
CDER’s Accelerating Rare disease Cures (ARC) Program via @YouTube
$NWBO #DCVaxL #GBM #orphandesignation
CDER’s Accelerating Rare disease Cures (ARC) Program via @YouTube
$NWBO #DCVaxL #GBM #orphandesignation
Accelerating Rare disease Cures (ARC) Program
CDER's ARC Program | Center for Drug Evaluation and Research (CDER)
fda.gov/about-fda/cent…
CDER's ARC Program | Center for Drug Evaluation and Research (CDER)
fda.gov/about-fda/cent…
‘I’m just carrying on’: vaccine gives brain cancer patient years of extra life
The revolutionary DCVax-L vaccine has allowed Nigel French to live a normal life seven years after a brain cancer diagnosis #DCVaxL $NWBO #CancerVaccine #Glioblastoma #Phase3
theguardian.com/science/2022/n…
The revolutionary DCVax-L vaccine has allowed Nigel French to live a normal life seven years after a brain cancer diagnosis #DCVaxL $NWBO #CancerVaccine #Glioblastoma #Phase3
theguardian.com/science/2022/n…
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma $NWBO #DCVaxL #CancerVaccine #GBM
A Phase 3 Prospective Externally Controlled Cohort Trial
jamanetwork.com/journals/jamao…
A Phase 3 Prospective Externally Controlled Cohort Trial
jamanetwork.com/journals/jamao…
More long-term Survivors, $NWBO #DCVaxL a personalized general therapeutic #CancerVaccine to treat any kind of solid tumor cancer anywhere in the body.
Exploring Adjuvants with #DCVaxL: POLY ICLC TLR 3 Agonist adjuvant discussion, #DrLindaLiau, early trial P 1. Using adjuvants w/ #DCVaxL $NWBO #Murcidencel #DCVax
Survival Data w/Adjuvants, small early trial:
Survival Data w/Adjuvants, small early trial:
Fuller Discussion re early trial with #DCVaxL + adjuvants, including Poly ICLC:
Re single agent checkpoint inhibitors, without DCVaxL, in Glioblastoma:
And the road to @MICCAI_Society @MiccaiS #Singapore has started! Cannot wait to present #ImagineQuant @YaleRadiology #BrainLesWorkshop 20 hrs travel totally worth it 😅😎❤️ to learn from the best #MICCAI22. @ujjwalbaid0408 @SpyridonBakas
#BrainLesWorkshop @MICCAI_Society @MiccaiStudents @WomenInMICCAI #ClinicalTranslation of #ML, #PACS based ML, #Neuroradiology, #GBM, Asking questions that address #radiologists & #oncologists real clinical needs! 🎊🦄🎉 #Industry #Collab @MingDeLin1234 brainlesion-workshop.org
Goodbye #Newark #NYC, looking forward to #Tokyo in 12 hrs! Dreams do come true!!! #academiclife #neurorad Thinking of @hsairmd @sairaallapeikko @theASFNR #Maui just about now! Will have to finish that episode 13 soon! @MICCAI_Society @MiccaiStudents @WomenInMICCAI #ImagineQuant
1/ Re $NWBO and #DCVaxL aka "ATL-DC" in brief:
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
2/ $NWBO and UCLA have a patent application pending approval for immunotherapy combinations with #DCVaxL.
3/ The #DCVaxLComboTrial appears to be intended to further the patent process and also to likely advance new commercial opportunities, including potential partnerships, for $NWBO. Many commentators have suggested some obvious potential partners.
1) Welcome to a new #accredited #tweetorial on the #goKDIGO guidance regarding evaluation and management of focal segmental glomerulosclerosis (#FSGS)--one of the most common causes of primary glomerular disease in adults. Leading us through this material is @edgarvlermamd.
2) Dr. Lerma is core faculty at both @ckd_ce & @cardiomet_CE and is an expert #nephrologist and #educator. This tweetorial is accredited for 0.5h CE/#CME for #physicians #nurses #NPs #PAs #pharmacists. Please follow along!
3) This educational program is supported by grants from Travere, Bayer, & Otsuka, and is intended for healthcare providers. Faculty disclosures can be found at ckd-ce.com/disclosures/. Past programs, still available for CE/#CME credit, are at ckd-ce.com.
Proud of this @NatureMedicine collaboration with #FeedmanLab on a novel method detecting early stage RCC in plasma&urine w/cell-free DNA methylomes. Work led by super stars @PierVitaleNuzzo @Jberchuck @keegankorthauer #SandorSpisak
1/ RCC kills 175,000 patients worldwide with no screening test available acsjournals.onlinelibrary.wiley.com/doi/full/10.33….
A screening test that detects RCC while still localized (2/3 RCCs) will possibly reduce mortality. RCC and CNS tumors do not shed much cfDNA in the blood!
A screening test that detects RCC while still localized (2/3 RCCs) will possibly reduce mortality. RCC and CNS tumors do not shed much cfDNA in the blood!
2/ Developed initially by @decarvalho_lab (co-senior author), we validated this ultra-sensitive cfMeDIP-seq using plasma cfDNA and, for the 1st time, cfDNA from urine samples collected in our #GelbCenter (Chair M. Pomerantz)
